论文部分内容阅读
肝肿瘤的早期诊断有助于手术切除,有人报道肝细胞癌(HCC)术后五年存活率为17％,较小的转移肝癌术后五年存活率为33％,可见,肝肿瘤的早期诊断和治疗会直接影响病人的预后。根据肿瘤生物学标志进行早期诊断不亚于全身CT和血管造影术。例如:甲种胎儿蛋白(AFP)主要针对HCC,癌胚抗原(CEA)针对直肠结肠癌肝转移,但这两项检测在良性炎症疾病及严重吸烟情况下可出现假阳性,而且也不适合检测胆管癌。近来,Holmgren在介绍癌相关抗原CA-50时指出,在细胞恶变期间表面糖蛋白变性形成CA-50瘤胚抗原(oncofetalantigen),而后进入血液循环。本文旨在研究CA-50RIA抑制试验对原继发肝肿瘤、良性肝脏疾患和正常人的诊断效果。
The early diagnosis of liver tumors is helpful for surgical resection. It has been reported that the five-year survival rate of hepatocellular carcinoma (HCC) after surgery is 17%, and that of the smaller metastatic hepatocellular carcinoma after surgery is 33%. It can be seen that the early stage of liver tumors can be seen. Diagnosis and treatment will directly affect the patient’s prognosis. Early diagnosis based on tumor biomarkers is no less than systemic CT and angiography. For example, AFP is mainly for HCC, and carcinoembryonic antigen (CEA) is for colorectal cancer liver metastasis. However, these two tests may be false positive in benign inflammatory diseases and severe smoking, and are not suitable for detection. Cholangiocarcinoma. Recently, Holmgren introduced the cancer-associated antigen CA-50 and pointed out that the surface glycoprotein denatured to form CA-50 oncofetal antigen during cell malignancy and then entered the blood circulation. This article aims to investigate the diagnostic efficacy of the CA-50RIA inhibition test for primary secondary liver tumors, benign liver diseases, and normal individuals.